<p>随着全球市场在潜在降息和经济指标变化的复杂性中航行，亚洲科技行业吸引了投资者的显著关注，尤其是在中美贸易关系改善的背景下，中国股市录得显著涨幅。在这种情况下，识别高增长科技股需要寻找能够利用当前市场动态的公司，例如技术进步和有利的监管环境。</p>
<h3>亚洲十大高增长科技公司</h3>
<table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>迅博科技</td>
<td>22.79%</td>
<td>22.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>PharmaEssentia</td>
<td>31.53%</td>
<td>65.34%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fositek</td>
<td>33.77%</td>
<td>43.92%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Eoptolink Technology</td>
<td>29.67%</td>
<td>32.15%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>富士康工业互联网</td>
<td>27.61%</td>
<td>27.23%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>金环电子</td>
<td>26.64%</td>
<td>35.16%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>盛宜电子</td>
<td>23.36%</td>
<td>30.38%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLLLtd</td>
<td>25.02%</td>
<td>24.93%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>ALTEOGEN</td>
<td>53.33%</td>
<td>71.63%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>100.40%</td>
<td>118.16%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们亚洲高增长科技和人工智能股票筛选器中的 178 只股票的完整列表。</p>
<p>让我们回顾一些我们筛选出的显著股票。</p>
<h2>Gan &amp; Lee Pharmaceuticals (SHSE:603087)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Gan &amp; Lee Pharmaceuticals 是一家生物制药公司，专注于在中国研发、生产和销售胰岛素类似物原料药和注射剂，市值为 410.1 亿人民币。</p>
<p><strong>运营：</strong> 公司的主要收入来源于胰岛素及相关产品的开发、生产和销售，收入为 38 亿人民币。</p>
<p>Gan &amp; Lee Pharmaceuticals 作为糖尿病护理高增长领域的参与者，展示了强劲的半年业绩，销售额从 13.1 亿人民币飙升至 20.7 亿人民币，净收入翻倍至 6.0368 亿人民币。这一财务增长得益于战略性产品发布，如在阿根廷新批准的胰岛素天冬氨酸注射剂——考虑到该国日益严重的糖尿病流行和医疗成本，这一举措具有重要意义。该公司致力于扩大其在拉丁美洲的市场足迹，彰显其在应对全球医疗需求方面的积极态度，使其在充满挑战的市场动态中具备持续增长的良好前景。</p>
<ul>
<li>点击这里深入了解 Gan &amp; Lee Pharmaceuticals 的完整分析健康报告。</li>
<li>通过我们的历史报告获取 Gan &amp; Lee Pharmaceuticals 的过去趋势和表现的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7a10c09c-0ce0-4521-983e-db4cac70f1be/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7a10c09c-0ce0-4521-983e-db4cac70f1be/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:603087 截至 2025 年 8 月的盈利和收入增长</p>
<h2>日联科技集团 (SHSE:688531)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 日联科技集团有限公司专注于在中国研发、制造和销售 X 射线技术和智能检测设备，市值为 96.9 亿人民币。</p>
<p><strong>运营：</strong> 日联科技集团专注于开发和销售 X 射线技术和智能检测设备。该公司在中国运营，利用其在先进成像解决方案方面的专业知识，满足各种工业应用的需求。</p>
<p>在亚洲繁忙的科技环境中，日联科技集团凭借显著的财务举措和增长指标脱颖而出。最近，该公司宣布了一项价值 2000 万人民币的股票回购计划，以增强股权激励，并调整回购价格以提升股东价值。这一战略性财务举措与其 25.8% 的强劲年收入增长和 28.1% 的盈利激增相辅相成，显著超越了中国市场的平均水平。随着研发费用与这些增长数据紧密对接，日联不仅在跟上步伐，还在科技行业内设定了基准，承诺在竞争激烈的行业动态中展现出引人注目的未来轨迹。</p>
<ul>
<li>点击这里通过我们的综合健康报告深入了解日联科技集团的复杂情况。</li>
<li>检查日联科技集团的历史表现报告，以了解其过去的表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f86d725e-5cf5-4572-9dda-83a9af42fbe8/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f86d725e-5cf5-4572-9dda-83a9af42fbe8/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688531 截至 2025 年 8 月的盈利和收入增长</p>
<h2>武汉达梦数据库 (SHSE:688692)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 武汉达梦数据库有限公司专注于在中国提供数据库产品开发服务，市值为 279.8 亿人民币。</p>
<p><strong>运营：</strong> 该公司的收入主要来自数据处理服务，金额为 11.4 亿人民币。</p>
<p>武汉达梦数据库在竞争激烈的科技环境中保持了强劲的增长轨迹，过去一年年收入增长 22.6%，盈利增长 28.3%，超越了软件行业平均下降 0.6% 的水平。尽管面临挑战，预计盈利增长略低于中国市场预测的 22.5%，而市场的预测为 25.3%，但其对创新的承诺显而易见，研发投资与这些财务指标紧密对接。该公司最近的战略举措，包括召开特别股东大会和宣布今天的半年度业绩，突显了其在不断变化的行业动态中加强市场地位和股东沟通的积极态度。</p>
<ul>
<li>点击这里解锁我们对武汉达梦数据库股票分析的全面见解。</li>
<li>查看我们的历史表现报告，以获取武汉达梦数据库过去表现的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f68591b8-9a91-4950-910d-cbaccb637d75/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f68591b8-9a91-4950-910d-cbaccb637d75/chart/revenue-and-expenses-breakdown"/></p>
<p>SHSE:688692 收入和支出明细截至 2025 年 8 月</p>
<h2>总结</h2>
<ul>
<li>在这里探索我们亚洲高增长科技和人工智能股票筛选器中的 178 个公司。</li>
<li>已经拥有这些公司？通过将您的投资组合与 Simply Wall St 连接，清晰化您的投资决策，轻松监控您股票的所有重要指标。</li>
<li>利用 Simply Wall St 最大化您的投资潜力，这是一款提供全球市场洞察的综合应用，免费使用。</li>
</ul>
<h2>寻找新的视角？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

日联科技

<p>亚洲科技行业因美中贸易关系改善和中国股市显著上涨而吸引了更多投资者的关注。关键的高增长科技公司包括 Gan & Lee Pharmaceuticals、日联科技和武汉大梦数据库，它们都展现出强劲的收入和盈利增长。Gan & Lee 专注于糖尿病护理，日联科技专注于 X 射线技术，而武汉大梦则提供数据库服务。这些公司在当前市场动态和技术进步中处于良好位置，使其成为该地区具有吸引力的投资选择</p>

<p>As global markets navigate the complexities of potential rate cuts and shifting economic indicators, the Asian tech sector has seen a notable surge in investor interest, particularly as Chinese stock markets have recorded significant gains amid improved U.S.-China trade relations. In this context, identifying high-growth tech stocks involves looking for companies that can capitalize on current market dynamics such as technological advancements and favorable regulatory environments.</p>
<div class="lb-trans"><p>随着全球市场在潜在降息和经济指标变化的复杂性中航行，亚洲科技行业吸引了投资者的显著关注，尤其是在中美贸易关系改善的背景下，中国股市录得显著涨幅。在这种情况下，识别高增长科技股需要寻找能够利用当前市场动态的公司，例如技术进步和有利的监管环境。</p>
</div><h3>Top 10 High Growth Tech Companies In Asia</h3>
<div class="lb-trans"><h3>亚洲十大高增长科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accton Technology</td>
<td>22.79%</td>
<td>22.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>PharmaEssentia</td>
<td>31.53%</td>
<td>65.34%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fositek</td>
<td>33.77%</td>
<td>43.92%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Eoptolink Technology</td>
<td>29.67%</td>
<td>32.15%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Foxconn Industrial Internet</td>
<td>27.61%</td>
<td>27.23%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Gold Circuit Electronics</td>
<td>26.64%</td>
<td>35.16%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>23.36%</td>
<td>30.38%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLLLtd</td>
<td>25.02%</td>
<td>24.93%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>ALTEOGEN</td>
<td>53.33%</td>
<td>71.63%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>100.40%</td>
<td>118.16%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>迅博科技</td>
<td>22.79%</td>
<td>22.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>PharmaEssentia</td>
<td>31.53%</td>
<td>65.34%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fositek</td>
<td>33.77%</td>
<td>43.92%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Eoptolink Technology</td>
<td>29.67%</td>
<td>32.15%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>富士康工业互联网</td>
<td>27.61%</td>
<td>27.23%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>金环电子</td>
<td>26.64%</td>
<td>35.16%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>盛宜电子</td>
<td>23.36%</td>
<td>30.38%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLLLtd</td>
<td>25.02%</td>
<td>24.93%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>ALTEOGEN</td>
<td>53.33%</td>
<td>71.63%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>100.40%</td>
<td>118.16%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 178 stocks from our Asian High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们亚洲高增长科技和人工智能股票筛选器中的 178 只股票的完整列表。</p>
</div><p>Let's review some notable picks from our screened stocks.</p>
<div class="lb-trans"><p>让我们回顾一些我们筛选出的显著股票。</p>
</div><h2>Gan &amp; Lee Pharmaceuticals (SHSE:603087)</h2>
<div class="lb-trans"><h2>Gan &amp; Lee Pharmaceuticals (SHSE:603087)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Gan &amp; Lee Pharmaceuticals is a biopharmaceutical company focused on the research, development, production, and sale of insulin analog APIs and injections in China, with a market cap of CN¥41.01 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Gan &amp; Lee Pharmaceuticals 是一家生物制药公司，专注于在中国研发、生产和销售胰岛素类似物原料药和注射剂，市值为 410.1 亿人民币。</p>
</div><p><strong>Operations:</strong> The company's primary revenue stream is derived from the development, production, and sales of insulin and related products, generating CN¥3.80 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的主要收入来源于胰岛素及相关产品的开发、生产和销售，收入为 38 亿人民币。</p>
</div><p>Gan &amp; Lee Pharmaceuticals, a player in the high-growth sector of diabetes care, showcased robust half-year results with sales soaring to CNY 2.07 billion from CNY 1.31 billion and net income doubling to CNY 603.68 million. This financial upswing is backed by strategic product launches like the newly approved insulin aspart injection in Argentina—a significant move considering the country's rising diabetes prevalence and healthcare costs. The firm's commitment to expanding its Latin American footprint underscores its proactive approach in addressing global healthcare needs, positioning it well for sustained growth amidst challenging market dynamics.</p>
<div class="lb-trans"><p>Gan &amp; Lee Pharmaceuticals 作为糖尿病护理高增长领域的参与者，展示了强劲的半年业绩，销售额从 13.1 亿人民币飙升至 20.7 亿人民币，净收入翻倍至 6.0368 亿人民币。这一财务增长得益于战略性产品发布，如在阿根廷新批准的胰岛素天冬氨酸注射剂——考虑到该国日益严重的糖尿病流行和医疗成本，这一举措具有重要意义。该公司致力于扩大其在拉丁美洲的市场足迹，彰显其在应对全球医疗需求方面的积极态度，使其在充满挑战的市场动态中具备持续增长的良好前景。</p>
</div><ul>
<li>Delve into the full analysis health report here for a deeper understanding of Gan &amp; Lee Pharmaceuticals.</li>
<li>Gain insights into Gan &amp; Lee Pharmaceuticals' past trends and performance with our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里深入了解 Gan &amp; Lee Pharmaceuticals 的完整分析健康报告。</li>
<li>通过我们的历史报告获取 Gan &amp; Lee Pharmaceuticals 的过去趋势和表现的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7a10c09c-0ce0-4521-983e-db4cac70f1be/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/7a10c09c-0ce0-4521-983e-db4cac70f1be/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:603087 Earnings and Revenue Growth as at Aug 2025</p>
<div class="lb-trans"><p>SHSE:603087 截至 2025 年 8 月的盈利和收入增长</p>
</div><h2>Unicomp Technology Group (SHSE:688531)</h2>
<div class="lb-trans"><h2>日联科技集团 (SHSE:688531)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Unicomp Technology Group Co., Ltd. specializes in the research, development, manufacture, and sale of X-ray technology and intelligent detection equipment in China with a market capitalization of CN¥9.69 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 日联科技集团有限公司专注于在中国研发、制造和销售 X 射线技术和智能检测设备，市值为 96.9 亿人民币。</p>
</div><p><strong>Operations:</strong> Unicomp Technology Group focuses on developing and selling X-ray technology and intelligent detection equipment. The company operates in China, leveraging its expertise in advanced imaging solutions to cater to various industrial applications.</p>
<div class="lb-trans"><p><strong>运营：</strong> 日联科技集团专注于开发和销售 X 射线技术和智能检测设备。该公司在中国运营，利用其在先进成像解决方案方面的专业知识，满足各种工业应用的需求。</p>
</div><p>Unicomp Technology Group, amid a bustling tech landscape in Asia, is distinguishing itself with notable financial maneuvers and growth metrics. Recently, the company announced a share repurchase program valued at CNY 20 million to bolster equity incentives, adjusting its buyback price to enhance shareholder value. This strategic financial play complements its robust annual revenue growth of 25.8% and earnings surge of 28.1%, outpacing the Chinese market averages significantly. With R&amp;D expenses aligning closely with these growth figures, Unicomp is not just keeping pace but setting benchmarks within the tech sector, promising an intriguing future trajectory amidst competitive industry dynamics.</p>
<div class="lb-trans"><p>在亚洲繁忙的科技环境中，日联科技集团凭借显著的财务举措和增长指标脱颖而出。最近，该公司宣布了一项价值 2000 万人民币的股票回购计划，以增强股权激励，并调整回购价格以提升股东价值。这一战略性财务举措与其 25.8% 的强劲年收入增长和 28.1% 的盈利激增相辅相成，显著超越了中国市场的平均水平。随着研发费用与这些增长数据紧密对接，日联不仅在跟上步伐，还在科技行业内设定了基准，承诺在竞争激烈的行业动态中展现出引人注目的未来轨迹。</p>
</div><ul>
<li>Navigate through the intricacies of Unicomp Technology Group with our comprehensive health report here.</li>
<li>Examine Unicomp Technology Group's past performance report to understand how it has performed in the past.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里通过我们的综合健康报告深入了解日联科技集团的复杂情况。</li>
<li>检查日联科技集团的历史表现报告，以了解其过去的表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f86d725e-5cf5-4572-9dda-83a9af42fbe8/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/f86d725e-5cf5-4572-9dda-83a9af42fbe8/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688531 Earnings and Revenue Growth as at Aug 2025</p>
<div class="lb-trans"><p>SHSE:688531 截至 2025 年 8 月的盈利和收入增长</p>
</div><h2>Wuhan Dameng Database (SHSE:688692)</h2>
<div class="lb-trans"><h2>武汉达梦数据库 (SHSE:688692)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Wuhan Dameng Database Company Limited specializes in database product development services in China and has a market cap of CN¥27.98 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 武汉达梦数据库有限公司专注于在中国提供数据库产品开发服务，市值为 279.8 亿人民币。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from data processing services, amounting to CN¥1.14 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司的收入主要来自数据处理服务，金额为 11.4 亿人民币。</p>
</div><p>Wuhan Dameng Database has been navigating the competitive tech landscape with a robust growth trajectory, evidenced by a 22.6% annual revenue increase and a 28.3% surge in earnings over the past year, surpassing the software industry's average decline of 0.6%. Despite facing challenges with an expected earnings growth slightly below the Chinese market forecast at 22.5%, compared to the market’s 25.3%, its commitment to innovation is clear with significant R&amp;D investments aligning closely with these financial metrics. The company’s recent strategic moves, including hosting a special shareholders meeting and announcing upcoming half-year results on today's date, underscore its proactive stance in strengthening market position and shareholder communications amidst evolving industry dynamics.</p>
<div class="lb-trans"><p>武汉达梦数据库在竞争激烈的科技环境中保持了强劲的增长轨迹，过去一年年收入增长 22.6%，盈利增长 28.3%，超越了软件行业平均下降 0.6% 的水平。尽管面临挑战，预计盈利增长略低于中国市场预测的 22.5%，而市场的预测为 25.3%，但其对创新的承诺显而易见，研发投资与这些财务指标紧密对接。该公司最近的战略举措，包括召开特别股东大会和宣布今天的半年度业绩，突显了其在不断变化的行业动态中加强市场地位和股东沟通的积极态度。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Wuhan Dameng Database stock in this health report.</li>
<li>Review our historical performance report to gain insights into Wuhan Dameng Database's's past performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里解锁我们对武汉达梦数据库股票分析的全面见解。</li>
<li>查看我们的历史表现报告，以获取武汉达梦数据库过去表现的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f68591b8-9a91-4950-910d-cbaccb637d75/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/f68591b8-9a91-4950-910d-cbaccb637d75/chart/revenue-and-expenses-breakdown"/></p>
<p>SHSE:688692 Revenue and Expenses Breakdown as at Aug 2025</p>
<div class="lb-trans"><p>SHSE:688692 收入和支出明细截至 2025 年 8 月</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>总结</h2>
</div><ul>
<li>Explore the 178 names from our Asian High Growth Tech and AI Stocks screener here.</li>
<li>Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.</li>
<li>Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里探索我们亚洲高增长科技和人工智能股票筛选器中的 178 个公司。</li>
<li>已经拥有这些公司？通过将您的投资组合与 Simply Wall St 连接，清晰化您的投资决策，轻松监控您股票的所有重要指标。</li>
<li>利用 Simply Wall St 最大化您的投资潜力，这是一款提供全球市场洞察的综合应用，免费使用。</li>
</ul>
</div><h2>Searching for a Fresh Perspective?</h2>
<div class="lb-trans"><h2>寻找新的视角？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

探索亚洲高增长科技股，精选三大领先选择